Navigation Links
NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women
Date:10/23/2011

BOSTON Postmenopausal women who reported having used nonsteroidal anti-inflammatory drugs for at least 10 years at the time of enrollment in the Women's Health Initiative study had a lower risk for death from colorectal cancer compared with women who reported no use of these drugs at enrollment, according to data presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011.

"Our results suggest that nonsteroidal anti-inflammatory drug (NSAID) use is associated with lower colorectal cancer mortality among postmenopausal women who use these medications more consistently and for longer periods of time," said Anna E. Coghill, M.P.H., a doctoral student in epidemiology at the University of Washington and Fred Hutchinson Cancer Research Center.

She and her colleagues evaluated the association between aspirin and nonaspirin NSAID use and colorectal cancer mortality in 160,143 postmenopausal women enrolled in the Women's Health Initiative (WHI) who did not report a history of colorectal cancer at baseline. The study population included women enrolled in the WHI clinical trials and women enrolled in the WHI observational study.

"The WHI study population represents a large and well-characterized cohort of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use," Coghill said.

Researchers confirmed 2,119 cases of colorectal cancer through medical reports and verified 492 deaths due to colorectal cancer through a centralized medical record and death certificate review.

Coghill and colleagues found that reported use of NSAIDs such as aspirin, ibuprofen and prescription NSAIDs at baseline, by itself, was not associated with colorectal cancer mortality.

However, women in the study who reported using NSAIDs at both study enrollment and three years after study enrollment had an approximately 30 percent lower rate of death due to colorectal cancer compared with women who reported no NASID use or use at only one of these two time points. Researchers also observed significant reductions in colorectal cancer mortality among women who reported at least 10 years of NSAID use at study enrollment compared with those who reported no use.

"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer," Coghill said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. NSAIDs Wont Shield Against Skin Cancer
2. NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs
3. Pitt study finds NSAIDs cause stem cells to self-destruct, preventing colon cancer
4. Long-term NSAID use by hypertensive patients with CAD increases risk of adverse events
5. NSAIDs May Raise Miscarriage Risk: Study
6. NSAID Painkillers Linked to Risk of Kidney Cancer
7. Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use
8. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
9. Certain pain medications do not appear to be associated with skin cancer risk
10. News brief: ALDH associated with worse overall survival in patients with pancreatic adenocarcinoma
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... it will co-exhibit with technology partners LG Business Solutions at ATARC Federal ... Center in Washington D.C., will provide education and examination into the mobility tools ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, ... coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a business ... the April edition of American Veterinarian™. , “We look forward to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a leading provider ... a row; they are the recipient of the prestigious “Best Overall Design Strategy ... award at Design Connections 2017. Top A&D professionals from leading firms, furniture manufacturers ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... testing methods are complicated and require expert user knowledge. In a live webinar ... dedicated to the simplified, yet highly accurate, determination of sodium. , It has ...
(Date:3/27/2017)... Fla. (PRWEB) , ... March 27, 2017 , ... The ... and the number of homeowners utilizing DIY and unlicensed contractors for renovations is also ... remodel or replacement project in 2015, and of those, 42% failed to use a ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... Research and Markets has announced the ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report ... cell therapy manufacturing and focuses both on contract manufacturers and ... anticipated to emerge as viable alternatives to conventional treatment options. ...
Breaking Medicine Technology: